KAE609 (Cipargamin)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Uncomplicated Plasmodium Falciparum Malaria

Phase 2

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

RecruitingNCT05750628

Novartis PharmaceuticalsUncomplicated Plasmodium Falciparum Malaria

Start: 2024-01-23End: 2026-06-23Target: 327Updated: 2025-07-30

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)

CompletedNCT07811882

Novartis PharmaceuticalsUncomplicated Plasmodium Falciparum Malaria

Start: 2025-10-10End: 2026-07-01Updated: 2026-09-10